3,369 results match your criteria Myeloid Sarcoma


Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor.

J Oncol Pharm Pract 2022 Jun 23:10781552221110826. Epub 2022 Jun 23.

103564Facultad de Medicina y Hospital Universitario "Dr José Eleuterio González" Haematology service, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Case Report: We report the first case of orbital myeloid sarcoma that was successfully treated with a standard venetoclax dose of 25%. A 38-year-old man with acute myeloid leukemia (AML) post-haplo-hematopoietic stem cell transplantation (HSCT) presented with a nine-month history of progressive right proptosis and a visual acuity deficit. The patient was treated with venetoclax (100 mg orally on days 1-28), cytarabine (40 mg subcutaneously, days 1-10), and itraconazole (100 mg twice daily orally on days 1-28). Read More

View Article and Full-Text PDF

Unusual presentations of central nervous system myeloid sarcoma.

Intern Med J 2022 Jun;52(6):1083-1088

Department of Neurology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Myeloid sarcoma (MS), also termed 'chloroma' or 'granulocytic sarcoma', is a tumour mass consisting of myeloid blasts occurring at an anatomical site other than the bone marrow. MS occurs in up to 8% of patients with acute myeloid leukaemia. While MS typically involves the skin or lymph nodes, almost any tissue can be affected, and symptoms largely depend on the organ involved and subsequent mass effect. Read More

View Article and Full-Text PDF

Identification of RCC1- LCK as a novel fusion gene in pediatric erythroid sarcoma.

Pediatr Blood Cancer 2022 Jun 17:e29848. Epub 2022 Jun 17.

Department of Pediatrics, Kyoto Prefectural University of Medicine.

Erythroid sarcoma is a very rare subtype of myeloid sarcoma with undetermined biological features. Here, we present an infant with a multifocal erythroid sarcoma, diagnosed because the tumor cells were positive for glycophorin A. After acute myeloid leukemia-oriented chemotherapy and surgical resection followed by cord blood transplantation, he has successfully maintained complete remission without any late effects. Read More

View Article and Full-Text PDF

Granulocytic sarcoma of cervix: A rare case report.

Medicine (Baltimore) 2022 Jun 17;101(24):e29419. Epub 2022 Jun 17.

Department of Gynecology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China.

Rationale: Granulocytic sarcoma (GS) is an uncommon extramedullary tumor, and involvement of the female reproductive system is very rare.

Patient Concerns: We present a case of cervical GS in a 45-year-old woman who presented with repeated vaginal bleeding after sex for 1 month.

Diagnosis: The patient was diagnosed with cervical GS mainly based on pathological immunohistochemical examination and further progressed to acute myeloid leukemia (AML) based on bone marrow puncture and cytogenetic analysis. Read More

View Article and Full-Text PDF

The DNA methylation landscape of five pediatric-tumor types.

PeerJ 2022 10;10:e13516. Epub 2022 Jun 10.

Department of Biology, Brigham Young University, Provo, Utah, United States.

Fewer DNA mutations have been identified in pediatric tumors than in adult tumors, suggesting that alternative tumorigenic mechanisms, including aberrant DNA methylation, may play a prominent role. In one epigenetic process of regulating gene expression, methyl groups are attached at the 5-carbon of the cytosine ring, leading to 5-methylcytosine (5mC). In somatic cells, 5mC occurs mostly in CpG islands, which are often within promoter regions. Read More

View Article and Full-Text PDF

Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature.

Front Oncol 2022 25;12:886436. Epub 2022 May 25.

Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.

Background: Acute promyelocytic leukemia (APL) constitutes a serious hematological emergency necessitating rapid diagnosis and therapy to prevent lethal bleedings resulting from APL-induced thrombocytopenia and coagulopathy. Atypical manifestations of APL, such as extramedullary disease at first presentation, pose diagnostic challenges and delay the onset of appropriate therapy. Nevertheless, extramedullary manifestations of APL are mostly accompanied by blood count alterations pointing to an underlying hematological disease. Read More

View Article and Full-Text PDF

Bilateral Myeloid Sarcoma of the Breast: A Case Report With Radiological and Pathological Correlation.

Cureus 2022 May 4;14(5):e24731. Epub 2022 May 4.

Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, USA.

Myeloid sarcoma is a solid extramedullary mass of immature myeloid cells, often in patients with myeloid leukemia. Myeloid sarcoma of the breast is extremely uncommon, and bilateral involvement is even rarer. Myeloid sarcoma of the breast can mimic primary breast cancer, lymphoma, and other neoplasms. Read More

View Article and Full-Text PDF

Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy.

Clin Case Rep 2022 Jun 5;10(6):e05919. Epub 2022 Jun 5.

Hematology and Transplant Center University Hospital "San Giovanni di Dio e Ruggi d'Aragona" Salerno Italy.

Kaposi's sarcoma is associated with immunosuppression and human herpesvirus 8 infection, while rarely described in myeloid malignancies. Here, we illustrate a rare case of chronic myeloid leukemia treated with imatinib, a tyrosine kinase inhibitor, who developed a human herpesvirus 8-related Kaposi's sarcoma. Read More

View Article and Full-Text PDF

Myeloid sarcoma of the skull base: A case report and systematic literature review.

Surg Neurol Int 2022 27;13:220. Epub 2022 May 27.

Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.

Background: Myeloid sarcoma (MS), or chloroma, is a rare extramedullary malignant tumor that consists of undifferentiated granulocytic cells, and it is most commonly associated with acute myeloid leukemia (AML). Intracranial MS accounts for 0.4% of MS cases, and involvement of the skull base and visual dysfunction is rarely reported. Read More

View Article and Full-Text PDF

Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.

Front Immunol 2022 18;13:903461. Epub 2022 May 18.

Department of Clinical Laboratory, Tangdu Hospital, Air Force Medical University, Xi'an, China.

Objective: Adenosine deaminase (ADA) plays an important role in immune response, which includes two isoenzymes: ADA1 and ADA2. This study aims to explore the roles of ADA1 and ADA2 in cancers.

Methods: Human Protein Atlas (HPA) and Gene Expression Profiling Interactive Analysis (GEPIA2) databases were used to analyze the mRNA expression of ADA1 and ADA2 in human normal cells and tumor tissues. Read More

View Article and Full-Text PDF

[Successful treatment of myelodysplastic syndromes complicated by myeloid sarcoma with haploidentical allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide].

Rinsho Ketsueki 2022 ;63(5):341-346

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University.

Using post-transplant cyclophosphamide (PTCy-haplo), haploidentical allogeneic hematopoietic stem cell transplantation has shown a surge in popularity in recent years. There are, however, only a few reports of PTCy-haplo being used to treat myelodysplastic syndromes (MDS) that have been complicated by myeloid sarcoma (MS). An immuno-suppressive therapy was given to a 25-year-old man who was diagnosed with low-risk MDS in September 2007. Read More

View Article and Full-Text PDF

Immune contexture of paediatric cancers.

Eur J Cancer 2022 Jul 31;170:179-193. Epub 2022 May 31.

Institut d'Hématologie et d'Oncologie Pédiatrique (iHOPe), Centre Léon Bérard, Lyon, France; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Laboratoire de Recherche Translationelle en Immunothérapies, INSERM U1015, Gustave Roussy, Villejuif, France; Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Gustave Roussy, Villejuif, France; Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France. Electronic address:

Background: The clinical development of immune checkpoint-targeted immunotherapies has been disappointing so far in paediatric solid tumours. However, as opposed to adults, very little is known about the immune contexture of paediatric malignancies.

Methods: We investigated by gene expression and immunohistochemistry (IHC) the immune microenvironment of five major paediatric cancers: Ewing sarcoma (ES), osteosarcoma (OS), rhabdomyosarcoma (RMS), medulloblastoma (MB) and neuroblastoma (NB; 20 cases each; n = 100 samples total), and correlated them with overall survival. Read More

View Article and Full-Text PDF

Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act.

Oncologist 2022 03;27(2):135-143

Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA.

Background: Compared with their ensured counterparts, uninsured adolescents and young adults (AYAs) with cancer are more likely to present with advanced disease and have poor prognoses. The Patient Protection and Affordable Care Act (ACA), enacted in 2010, provided health care coverage to millions of uninsured young adults by allowing them to remain on their parents' insurance until age 26 years (the Dependent Care Expansion, DCE). The impact of the expansion of insurance coverage on survival outcomes for young adults with cancer has not been assessed. Read More

View Article and Full-Text PDF

Microtransplantation for myeloid sarcoma: Two case reports.

Leuk Res Rep 2022 21;17:100326. Epub 2022 May 21.

Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, #37 Guoxue Alley, Wuhou District, Chengdu 610041, Sichuan, China.

Myeloid sarcoma (MS), is a rare extramedullary tumor with a poor prognosis and high recurrence rate. Microtransplantation is one of the alternative methods of traditional transplantation, which does not rely on HLA complete matching, has low toxicity and may retain part of graft-versus-leukemia (GVL) effect. It has been reported that microtransplantation can significantly improve the survival rate of elderly AML patients. Read More

View Article and Full-Text PDF

The transformation of isolated gastric myeloid sarcoma into acute myeloid leukemia presenting with a complex karyotype and TLS-ERG gene fusion: A case report.

Medicine (Baltimore) 2022 May 27;101(21):e29475. Epub 2022 May 27.

Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China.

Rationale: Isolated myeloid sarcoma (MS) is characterized by the rapid proliferation of myeloblasts of acute myeloid leukemia (AML), without any blood or bone marrow involvement. This disease can manifest with extramedullary organ involvement, such as the skin, lymph nodes, bone, brain, breast cervix, and visceral organs, while the occurrence of myeloid sarcomas in the stomach is rare. Isolated MS has been associated with acute myeloid leukemia (AML), but the rapid progression of MS to acute myeloid leukemia with a complex karyotype and TLS-ERG fusion gene is even rarer. Read More

View Article and Full-Text PDF

Rare Case of Mixed Phenotype Acute Leukemia Presenting as a Myeloid Sarcoma Without Leukemic Involvement.

Perm J 2022 Apr 5;26(1):132-136. Epub 2022 Apr 5.

Department of Oncology/Hematology, Kaiser Permanente Santa Clara, Santa Clara, CA, USA.

Introduction: Mixed phenotype acute leukemia (MPAL) is a rare type of acute leukemia with immunophenotypic features of both myeloid-derived and lymphoid-derived lineages.

Case Presentation: We present an atypical case of a 32-year-old woman presenting with an anterior mediastinal mass and pericardial/pleural involvement that was initially diagnosed as primary mediastinal diffuse large B-cell lymphoma. However, flow cytometry on pleural fluid confirmed the diagnosis of MPAL of B-cell/myeloid lineage without peripheral blood/bone marrow involvement. Read More

View Article and Full-Text PDF

A Case of Isolated Myeloid Sarcoma Associated With Germline T790M Variant: The Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels.

J Hematol 2022 Apr 12;11(2):71-76. Epub 2022 Apr 12.

Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.

Isolated myeloid sarcoma is an uncommon subtype of acute myeloid leukemia associated with variable prognosis. We present the case of a previously healthy 30-year-old man presenting with chest pain and weight loss who was found to have a large mediastinal mass. Biopsy of the mass was consistent with isolated myeloid sarcoma. Read More

View Article and Full-Text PDF

Target Therapy for Extramedullary Relapse of -ITD Acute Myeloid Leukemia: Emerging Data from the Field.

Cancers (Basel) 2022 Apr 27;14(9). Epub 2022 Apr 27.

Division of Hematology, A.O.U. "Policlinico G.Rodolico-S.Marco", 95123 Catania, Italy.

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase family member. Mutations in , as well known, represent the most common genomic alteration in acute myeloid leukemia (AML), identified in approximately one-third of newly diagnosed adult patients. In recent years, this has represented an important therapeutic target. Read More

View Article and Full-Text PDF

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.

J Hematol Oncol 2022 May 13;15(1):60. Epub 2022 May 13.

Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic.

Background: Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed.

Methods: We retrospectively analyzed a large multi-center cohort of 1583 newly diagnosed AML patients, of whom 225 (14.21%) had EM. Read More

View Article and Full-Text PDF

Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis.

Cancer Epidemiol Biomarkers Prev 2022 Jun;31(6):1176-1184

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: There is a growing population of adolescent and young adult (AYA, age 15-39 years) acute leukemia survivors in whom long-term mortality outcomes are largely unknown.

Methods: The current study utilized the Surveillance, Epidemiology, and End Results (SEER) registry to assess long-term outcomes of AYA acute leukemia 5-year survivors. The impact of diagnosis age, sex, race/ethnicity, socioeconomic status, and decade of diagnosis on long-term survival were assessed utilizing an accelerated failure time model. Read More

View Article and Full-Text PDF

Mast cell neoplasm: a challenging pathological diagnosis.

Hum Pathol 2022 May 10;126:55-62. Epub 2022 May 10.

Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, 04501-000, Brazil; Laboratory of Investigative Pathology, CIPED, University of Campinas (Unicamp), Campinas, São Paulo, 13083-887, Brazil; Anatomic Pathology D'Or Hospitals Network, São Paulo, 04321-120, Brazil; Multipat Laboratory of Pathology, Campinas, São Paulo, 13086-130, Brazil.

Systemic mastocytosis (SM) is a myeloid neoplasm characterized by abnormal growth and accumulation of neoplastic mast cells in at least one extracutaneous site. Clinical presentation and course are variable, most patients are developing an indolent disease and some, an aggressive/leukemic form. Because of its rarity, most physicians are unfamiliar with this disease and do not readily diagnose it. Read More

View Article and Full-Text PDF

Chemotherapy as Treatment for Acute Myeloid Leukemia (AML)-Induced Facial Nerve Palsy.

Cureus 2022 Mar 31;14(3):e23710. Epub 2022 Mar 31.

Hematology and Medical Oncology, Henry Ford Health System, Detroit, USA.

Acute myeloid leukemia (AML) is a disorder of the myeloid cell line that can manifest infrequently as a granulocytic sarcoma with infiltration into bone and soft tissue. Consequently, cranial nerve neuropathy due to AML infiltration can result in variable neurological deficits, including facial nerve palsy. Here, we present the case of a patient presenting with unilateral facial nerve palsy with evidence of AML in cerebrospinal fluid (CSF) cytology and bilateral opacification of the mastoid air cells suggestive of AML infiltration into the mastoid process. Read More

View Article and Full-Text PDF

Hoxa11-mediated reduction of cell migration contributes to myeloid sarcoma formation induced by cooperation of MLL/AF10 with activating KRAS mutation in a mouse transplantation model: Hoxa11 in myeloid sarcoma formation.

Neoplasia 2022 Jul 29;29:100802. Epub 2022 Apr 29.

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan. Electronic address:

The molecular mechanism of myeloid sarcoma (MS) formation remains nuclear. Our clinical and mouse model findings from a previous study revealed that cooperation of KMT2A (MLL) translocation (MLL-t) with activating N-/K-RAS mutations promoted MS formation in a shorter latency. To improve the understanding of MS formation, in this study, we performed imaging cell trafficking analysis and demonstrated that cells harboring cooperating mutations migrated more slowly to omental adipose tissues and more cells were retained in adipose tissues in vivo. Read More

View Article and Full-Text PDF

[Radiotherapy for the treatment of leukemia].

Onkologe (Berl) 2022 Apr 25:1-7. Epub 2022 Apr 25.

Klinik für Strahlentherapie - Radioonkologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster, Deutschland.

Background: Lymphoma cells are highly radiosensitive and consequently, radiation therapy is a rational addition to systemic therapy in the treatment of leukemia. Especially as a conditioning regimen before allogeneic stem cell transplantation, radiation therapy, in the form of total body irradiation, is an established concept.

Objectives: The present work provides an overview on the execution and side effects of radiation treatment in leukemia. Read More

View Article and Full-Text PDF

Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.

Sci Rep 2022 04 26;12(1):6752. Epub 2022 Apr 26.

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.

Myeloid sarcoma is a rare manifestation of acute myeloid leukemia (AML) and is associated with poor overall survival (OS). The optimal treatment remains unclear. The study retrospectively evaluated 118 patients with myeloid sarcoma who were treated at the First Affiliated Hospital of Zhengzhou University from January 2010 to July 2021. Read More

View Article and Full-Text PDF

Extramedullary Acute Leukemia-Still an Unforeseen Presentation.

Hematol Rep 2022 Apr 18;14(2):143-148. Epub 2022 Apr 18.

Divino Espírito Santo's Hospital, 9500-370 Ponta Delgada, Portugal.

Myeloid sarcomas (MS) are rare extramedullary (EM) hematological tumors that generally arise during the natural course of acute myeloid leukemia (AML), occurring concomitantly with the onset of systemic leukemia; it can also occur following onset but rarely before. Common sites of EM involvement include the lymph nodes, skin, soft tissue, bone and peritoneum. Herein, we report the case of a 63-year-old man who presented EM AML upon initial diagnosis involving the bone marrow, lymph nodes and skin (leukemia cutis). Read More

View Article and Full-Text PDF

Subsequent malignant neoplasms in the pediatric age in retinoblastoma survivors in Argentina.

Pediatr Blood Cancer 2022 Aug 21;69(8):e29710. Epub 2022 Apr 21.

Hematology and Oncology Department, Hospital JP Garrahan, Buenos Aires, Argentina.

Background: Retinoblastoma survivors in low- and middle-income countries are exposed to high-intensity treatments that potentially place them at higher risk of early subsequent malignant neoplasms (SMNs).

Methods: We followed 714 (403 [56.4%] nonhereditary and 311 [43. Read More

View Article and Full-Text PDF

Consolidative opacity in a patient with acute leukemia.

Clin Case Rep 2022 Apr 4;10(4):e05694. Epub 2022 Apr 4.

Department of Pulmonary Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA.

27 year old man with newly diagnosed acute myeloid leukemia presents with new parenchymal consolidation. Although biopsy was precluded, diagnostic studies support myeloid sarcoma. Resolution of consolidation occurred with hematopoietic stem cell transplantation. Read More

View Article and Full-Text PDF